The company's principal activity is to develop medical systems and therapeutics to provide safer and more effective options to patients. It develops products based on its proprietary helinx(R) technology for controlling biological replication. Its most advanced programs are focused on systems to enhance the safety of the world's blood supply. The intercept blood system inactivates viruses, bacteria, other pathogens and white blood cells. In collaboration with its partner, baxter healthcare corporation, a ce mark has been received for this system. Regulatory submission process to obtain approval in the U.S. As well as preparations for the U.S. Regulatory submission for the intercept blood system for plasma, which will be followed by a ce mark application for this product, are underway. Phase iii clinical trials for intercept red blood cells are being conducted. Therapeutic applications of helinx technology to treat and prevent serious diseases are being pursued.
